170 related articles for article (PubMed ID: 10743281)
1. Developing a national system for dealing with adverse events following immunization.
Mehta U; Milstien JB; Duclos P; Folb PI
Bull World Health Organ; 2000; 78(2):170-7. PubMed ID: 10743281
[TBL] [Abstract][Full Text] [Related]
2. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
[TBL] [Abstract][Full Text] [Related]
3. Safety monitoring in vaccine development and immunization.
Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML
Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963
[TBL] [Abstract][Full Text] [Related]
4. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
[TBL] [Abstract][Full Text] [Related]
5. Reporting of adverse events following immunization in Australia.
Isaacs D; Lawrence G; Boyd I; Ronaldson K; McEwen J
J Paediatr Child Health; 2005 Apr; 41(4):163-6. PubMed ID: 15813867
[TBL] [Abstract][Full Text] [Related]
6. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
[TBL] [Abstract][Full Text] [Related]
7. The monitoring of adverse events following immunization.
Tatley M
N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
[No Abstract] [Full Text] [Related]
8. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
[TBL] [Abstract][Full Text] [Related]
9. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.
;
Expert Rev Vaccines; 2009 Jun; 8(6):705-16. PubMed ID: 19485752
[TBL] [Abstract][Full Text] [Related]
10. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
Miller M; Turner N
N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
[No Abstract] [Full Text] [Related]
11. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.
Gold MS; Gidudu J; Erlewyn-Lajeunesse M; Law B;
Vaccine; 2010 Jun; 28(28):4487-98. PubMed ID: 20434547
[TBL] [Abstract][Full Text] [Related]
12. Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
Graham JE; Borda-Rodriguez A; Huzair F; Zinck E
Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930
[TBL] [Abstract][Full Text] [Related]
13. Monitoring and assessing vaccine safety: a European perspective.
Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J
Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548
[TBL] [Abstract][Full Text] [Related]
14. The development of standardized case definitions and guidelines for adverse events following immunization.
Kohl KS; Gidudu J; Bonhoeffer J; Braun MM; Buettcher M; Chen RT; Drammeh B; Duclos P; Heijbel H; Heininger U; Hummelman E; Jefferson T; Keller-Stanislawski B; Loupi E; Marcy SM
Vaccine; 2007 Aug; 25(31):5671-4. PubMed ID: 17400339
[No Abstract] [Full Text] [Related]
15. Monitoring vaccine safety during an influenza pandemic.
Iskander J; Haber P; Herrera G
Yale J Biol Med; 2005 Oct; 78(5):265-75. PubMed ID: 17132333
[TBL] [Abstract][Full Text] [Related]
16. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database.
Letourneau M; Wells G; Walop W; Duclos P
Vaccine; 2008 Feb; 26(9):1185-94. PubMed ID: 18243428
[TBL] [Abstract][Full Text] [Related]
17. Vaccine adverse events in the new millennium: is there reason for concern?
Ward BJ
Bull World Health Organ; 2000; 78(2):205-15. PubMed ID: 10743286
[TBL] [Abstract][Full Text] [Related]
18. The "Green Channel" of the Veneto region as a model for vaccine safety monitoring in Italy.
Zanoni G; Ferro A; Valsecchi M; Tridente G
Vaccine; 2005 Mar; 23(17-18):2354-8. PubMed ID: 15755627
[TBL] [Abstract][Full Text] [Related]
19. [Adverse reactions to diphtheria-pertussis-tetanus vaccine in the Chilean Immunization Program].
Abarca V K; Cerda L J; Ferreccio R C
Rev Med Chil; 2009 Jan; 137(1):10-7. PubMed ID: 19399316
[TBL] [Abstract][Full Text] [Related]
20. Reporting vaccine-associated adverse events.
Duclos P; Hockin J; Pless R; Lawlor B
Can Fam Physician; 1997 Sep; 43():1551-6, 1559-60. PubMed ID: 9303234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
